Gozlan Lawrence Bernard 4

What Happened
Lawrence Bernard Gozlan, a director of Alterity Therapeutics Ltd (ATHE), was granted 1,000,000 derivative shares on June 15, 2026. The award shows an acquisition at $0.00 per share (a non‑cash grant/derivative award), so the filer paid no cash consideration in this transaction. This is an award/grant (code A) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Filing date (accession): 2026-06-23 (filed 8 days after the transaction). This is later than the SEC Form 4 two-business-day filing rule.
• Transaction type/code: A — Grant/Award of derivative securities (reported as derivative).
• Amount: 1,000,000 derivative shares acquired at $0.00 (no cash paid).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes/plan info: None provided in the supplied data.
• Timeliness note: Filing appears late relative to the standard two-business-day deadline; late filings can be reviewed by the SEC and may warrant corrective disclosure.

Context
An "A" derivative entry typically reflects a compensation award such as restricted stock units or another derivative grant; such awards do not necessarily indicate a personal market bet by the insider. If the award vests or converts to common shares later, it may then be tradable. Because no sale or purchase on the open market occurred, this is primarily a compensation event rather than immediate insider buying or selling.